UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 18, 2017
Argos Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| Delaware | | 001-35443 | | 56-2110007 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
4233 Technology Drive Durham, North Carolina 27704 | |
| (Address of Principal Executive Offices) | |
Registrant’s telephone number, including area code: (919) 287-6300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.x
Item 8.01 Other Events. On April 18 2017, the Company issued a press release announcing interim results from its Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma and providing additional perspective on its decision to continue the ADAPT trial notwithstanding the recommendation of the trial’s Independent Data Monitoring Committee that the study be discontinued for futility. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On April 18, 2017, the Company will host a conference call to discuss the interim results of its ADAPT trial and to answer questions. The Company made available a slide presentation to accompany the call. A copy of the Company’s slide presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ARGOS THERAPEUTICS, INC. |
| | | |
| | By: | /s/ Jeffrey D. Abbey |
| | Name: | Jeffrey D. Abbey |
| | Title: | President and Chief Executive Officer |
DATED: April 18, 2017
EXHIBIT INDEX
Exhibit
Number | | Description of Exhibit |
| | | |
| 99.1 | | Press Release, dated April 18, 2017, entitled “Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial” |
| 99.2 | | Slide Presentation, dated April 18, 2017, entitled “Results of February Interim Analysis of ADAPT Study and Perspective on Decision to Keep Trial Open” |
